Breast cancer drugs market to be valued at $57.1b by 2031

By end user, hospitals accounted for about 46% of the total market value.

The global breast cancer drugs market, valued at $32.4b in 2024, is expected to reach $57.1b by 2031 at a compound annual growth rate of 9.2%, according to a DataM Intelligence report.

The sector’s expansion is attributed to a shift in treatment approaches, with drug development increasingly focused on biomarker-based targeted therapies and immunotherapies.

“Instead of one-size-fits-all approaches, therapies are now selected based on hormone receptor status, HER2 expression, and emerging molecular signatures,” the report said.

In addition, continuous pipeline development, label expansions, and newer mechanisms of action are increasing per-patient drug value.

By end user, hospitals remained the dominant setting for breast cancer drug use, accounting for about 46% of total market value, or $14.9b.

“Complex treatment protocols, infusion therapies, and inpatient oncology care drive this dominance,” it added.

By cancer type, hormone receptor-positive breast cancer was the largest segment in 2024, accounting for around 64% of the total market value, or $20.b.

By therapy, targeted treatments represented the leading category, contributing approximately 38% of market revenue, equivalent to $12.3b.